Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21

Cancer Gene Therapy

Volumn 14, Issue 5, 2007, Pages 451-459

  Yamano, T ^a   Kaneda, Y ^b   Hiramatsu, S H ^a   Huang, S ^a   Tran, A N ^a   Giuliano, A E ^a   Hoon, D S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant; Breast cancer; CCL21; DNA vaccine; TERT

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LIPOSOME; PLASMID DNA; SECONDARY LYMPHOID TISSUE CHEMOKINE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; MICROENCAPSULATION; MONOTHERAPY; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOKINES, CC; CYTOKINES; FEMALE; FLOW CYTOMETRY; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; TELOMERASE; VACCINES, DNA;

MURINAE; SENDAI VIRUS;

EID: 34247118770     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701035     Document Type: Article

References (36)

1. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999; 170: 85-100.
2. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959.
3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
4. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
5. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147-5152.
6. Harada K, Kurisu K, Arita K, Sadatomo T, Tahara H, Tahara E et al. Telomerase activity in central nervous system malignant lymphoma. Cancer 1999; 86: 1050-1055.
7. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 452-459.
8. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-679.
9. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21: 674-679.
10. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97: 4796-4801.
11. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6: 1011-1017.
12. Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001; 31: 2642-2651.
13. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-8370.
14. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 2002; 62: 2600-2605.
15. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002; 62: 5041-5048.
16. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002; 168: 5900-5906.
17. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113: 425-433.
18. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10: 828-839.
19. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
20. Zhou WZ, Kaneda Y, Huang S, Morishita R, Hoon D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Therapy 1999; 6: 1768-1773.
21. Tanaka M,Kaneda Y,Fujii S,Yamano T,Hashimoto K, Huang SK et al. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 2002; 5: 291-299.
22. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of Immunity by a DNA Melanoma Vaccine against TRP2 with CCL21 as an Adjuvant. Mol Ther 2006; 13: 194-202.
23. Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170: 5188-5194.
24. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175-184.
25. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286: 2098-2102.
26. Nanni P, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Rossi I et al. Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Br J Cancer 1996; 74: 1564-1569.
27. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997; 71: 8497-8503.
28. del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15: 441-448.
29. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999; 162: 3915-3925.
30. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19: 182-186.
31. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102-3111.
32. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342-3345.
33. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146.
34. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65: 553-561.
35. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004; 27: 265-272.
36. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12: 33-42.